| WORCESTER – The Massachusetts Cannabis Control Commission (Commission) this week published the “Review and Assessment of the Massachusetts Adult- and Medical-use Cannabis Industries” report, a comprehensive review of the Commonwealth’s adult- and medical-use cannabis landscape based on more than six years of data.
The Industry Report, drafted and published to satisfy the Commission’s statutory research mandate, covers topics from product sales trends and testing data to demographic information for license owners and employees working in the regulated industry. The Commission’s Research Department, led by Chief of Research Dr. Julie Johnson, presented the report using datasets beginning with the inception and implementation of Massachusetts’ adult-use marijuana retailers in November 2018 up to April 2024.
The Industry Report, which was presented to Commissioners and the public at the agency’s Feb. 25 public meeting, also includes the first release of data on the medical market and patients, as well as cannabis product testing. The report was released prior to the Commission’s public listening session on the Medical Use of Marijuana Program on Feb.27, where the agency will hear from patients and Medical Marijuana Treatment Centers (MTCs) about the program and patient experience, as well as potential policy changes that could increase access to the program.
As the cannabis industry in Massachusetts marks significant recent milestones, including a $1.64 billion sales record in 2024, the release of proposed social consumption regulations, and the issuance of the 700th notice to commence operations in September 2024, the Industry Report provides data that will enhance the public’s understanding of how the regulated cannabis marketplace continues to evolve. |
